Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once Daily vs Conventional Asacol in Quiescent Ulcerative Colitis
NCT00343850Phase 3Completed
- Sponsor
- University of Chicago
- Start
- Sep 2006
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Salcrozine in ulcerative colitis (UC) (2 arms), sponsored by University of Chicago. Primary endpoints: Medication consumption rates (adherence) at 12 months, Disease relapse at 12 months and 1 more. Started Sep 2006; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00343850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343850.